Peramivir

Peramivir
Clinical data
Trade names	Rapivab
AHFS/Drugs.com	Monograph
License data	US DailyMed: Peramivir;
Pregnancy; category	AU: B3; ;
Routes of; administration	Intravenous
ATC code	J05AH03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	100% (IV)
Elimination half-life	7.7 to 20.8 hours (in patients with normal renal function)
Excretion	Kidney
Identifiers
	IUPAC name (1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-(carbamimidoylamino)-2-hydroxycyclopentanecarboxylic acid;
CAS Number	330600-85-6 ; trihydrate: 1041434-82-5 ;
PubChem CID	151164;
DrugBank	DB06614 ;
ChemSpider	135903 ;
UNII	9ZS94HQO3B; trihydrate: QW7Y7ZR15U ;
KEGG	D03829;
ChEBI	CHEBI:85202 ;
ChEMBL	ChEMBL332608 ;
CompTox Dashboard (EPA)	DTXSID10904727 ;
Chemical and physical data
Formula	C15H28N4O4
Molar mass	328.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)NC(=O)C;
	InChI InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1 ; Key:XRQDFNLINLXZLB-CKIKVBCHSA-N ;
	(what is this?) (verify)

Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.^[2]

In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of peramivir based on safety data from phase I, phase II, and limited phase III trial data. The emergency use authorization for peramivir expired in June 2010.^[3]^[4] On 19 December 2014, the FDA approved peramivir to treat influenza infection in adults.^[2]

^ "The flu". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^ ^a ^b Cite error: The named reference FDA approval was invoked but never defined (see the help page).
^ Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.
^ "Peramivir authorized for Emergency use". LifeHugger. 2009-12-04. Archived from the original on 2011-07-13. Retrieved 2009-12-04.

[1] "The flu". Health Canada. 9 May 2018. Retrieved 13 April 2024.

[FDA_approval-2] Cite error: The named reference FDA approval was invoked but never defined (see the help page).

[thorlund_syst_review-3] Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.

[4] "Peramivir authorized for Emergency use". LifeHugger. 2009-12-04. Archived from the original on 2011-07-13. Retrieved 2009-12-04.

[1]

[2]

[3]

[4]